Aktis Oncology, Inc.
$20.83
▲
1.76%
2026-04-21 05:12:00
www.aktisoncology.com
NMS: AKTS
Explore Aktis Oncology, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.08 B
Current Price
$20.83
52W High / Low
$29.16 / $14.72
Stock P/E
—
Book Value
$-159.68
Dividend Yield
—
ROCE
-31.96%
ROE
-29.45%
Face Value
—
EPS
$-1.21
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
79
Beta
—
Debt / Equity
6.17
Current Ratio
7.37
Quick Ratio
7.37
Forward P/E
-10.15
Price / Sales
143.61
Enterprise Value
$1.05 B
EV / EBITDA
-14.53
EV / Revenue
161.8
Rating
Strong Buy
Target Price
$32.5
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lisata Therapeutics, Inc. | $2.83 | — | $25.56 M | — | -124.1% | -75.53% | $5.07 / $1.81 | $1.68 |
| 2. | Adial Pharmaceuticals, Inc. | $1.63 | — | $2.33 M | — | -147.82% | -1.71% | $687.5 / $1.54 | $4.75 |
| 3. | Anixa Biosciences, Inc. | $3 | — | $100.58 M | — | -82.91% | -68.06% | $5.46 / $2.44 | $0.45 |
| 4. | Immunic, Inc. | $0.95 | — | $124.59 M | — | 1572.16% | -16.53% | $1.51 / $0.51 | $-0.06 |
| 5. | Celcuity Inc. | $120.09 | — | $5.8 B | — | -40.76% | -1.64% | $127.34 / $9.5 | $2.08 |
| 6. | Evogene Ltd. | $0.8 | — | $7.92 M | — | -84.53% | -1.01% | $2.42 / $0.72 | $-0.01 |
| 7. | Summit Therapeutics Inc. | $24.32 | — | $18.91 B | — | -161.37% | -2.06% | $36.91 / $13.83 | $0.85 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q4 2024 | |
|---|---|---|
| Sales | 1.87 M | 0.93 M |
| Operating Profit | -17.38 M | -15.63 M |
| Net Profit | -15.14 M | -12.06 M |
| EPS in Rs | -0.28 | -0.23 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 6.5 M | 1.49 M | 0 M | 0 M |
| Operating Profit | -74.68 M | -52.05 M | -34.79 M | -19.76 M |
| Net Profit | -63.73 M | -43.98 M | -28.64 M | -17.93 M |
| EPS in Rs | -1.19 | -0.82 | -0.54 | -0.34 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 264.88 M | 326.18 M | 122.36 M | 138.32 M |
| Total Liabilities | 411.03 M | 413.98 M | 168.66 M | 157.55 M |
| Equity | -146.15 M | -87.8 M | -46.31 M | -19.23 M |
| Current Assets | 230.31 M | 300.85 M | 100.2 M | 132.48 M |
| Current Liabilities | 31.24 M | 18.82 M | 6.24 M | 5.28 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -64.13 M | 14.76 M | -30 M | -18.12 M |
| Investing CF | 65.96 M | -190.4 M | -68.83 M | -2.31 M |
| Financing CF | -1.21 M | 183.28 M | 0 M | 119.98 M |
| Free CF | -73.71 M | 11.9 M | -33.77 M | -20.43 M |
| Capex | -9.58 M | -2.86 M | -3.76 M | -2.31 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 336.92% | — | — | — |
| Earnings Growth % | -44.91% | -53.56% | -59.75% | — |
| Profit Margin % | -980.93% | -2957.63% | — | — |
| Operating Margin % | -1149.52% | -3500.34% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1113.67% | -3394.42% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.